Cognios Capital’s DexCom DXCM Stock Holding History

Cognios Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-400	Closed	-$26K	–	77
2020 Q1	$26K	Buy	+400	New	+$24.9K	0.01%	208

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Cognios Capital's DXCM Position: Q2 2020 in Review

Cognios Capital sold out of DexCom (DXCM) in Q2 2020, closing a stake of 400 shares — an estimated $26K sold.

Cognios Capital first reported a position in DXCM in Q1 2020 and held it in 1 quarter. The position peaked at $26K in Q1 2020. 723 funds tracked by Wall St. Rank hold DXCM as of Q2 2020.

Cognios Capital reported no remaining DexCom position as of Q2 2020 after selling out during the quarter.
Cognios Capital sold 400 DexCom shares in Q2 2020, an estimated $26K.
Cognios Capital first reported a position in DexCom in Q1 2020 and held it in 1 quarter.
Cognios Capital's DexCom position peaked at $26K in Q1 2020.
723 funds tracked by Wall St. Rank held DexCom as of Q2 2020.

Based on Cognios Capital's 13F filing for Q2 2020.